A recent study found that CoQ10 phytosomes, marketed by Indena as Ubiqsome, improve cellular uniquinone uptake in skeletal muscle cells.
A recent study1 found that CoQ10 phytosomes, marketed by Indena as Ubiqsome, improve cellular uniquinone uptake in skeletal muscle cells. In the crossover design study, eight volunteers were randomized to receive either 100 mg per day of CoQ10 for two weeks, delivered in either a phytosome form as a lecithin formulation or CoQ10 crystalline form. Results showed that both formulations were equivalent in terms of plasma bioavailability in vivo, but in vitro, lipoproteins enriched with the phytosome form of CoQ10 saw a higher bioavailability than those enriched with the crystalline form in both human dermal fibroblasts and murine skeletal myoblast, suggesting that phytosome carriers may offer an advantage in delivering CoQ10 in skin and muscle tissues.
According to Indena, Ubiqsome is a food-grade delivery system for CoQ10 that is formulated using a proprietary “Multi-Talented Technology Platform” developed by the company. Serena Tongiani, Indena’s chief product officer said in a press release that this latest research builds on the body of scientific literature demonstrating the ingredient’s ability to enhance bioavailability of CoQ10 as well as endothelial function. “All the evidences we got in the last years, including the last ones recently issued, allow us to say that Ubiqsome CoQ10 Phytosome is a reliable and promising ingredient for all traditional applications of CoQ10,” said Tongiani in a press release.
Reference
Marcheggiani, F.; Orlando, P.; Silvestri, S.; Cirilli, I.; Riva, A.; Petrangolini, G.; Orsini, F.; Tiano, L. CoQ10 Phytosomes Improve Cellular Ubiquinone Uptake in Skeletal Muscle Cells: An Ex Vivo Study Using CoQ10-Enriched Low-Density Lipoproteins Obtained in a Randomized Crossover Study. Antioxidants, 2023, 12 (4): 964. DOI: 10.3390/antiox12040964
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.